View of Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years

Return to Article Details Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years Download Download PDF